This past week brought many analyst upgrades and downgrades. 24/7 Wall St reviews dozens of analyst research reports each day of the week and hundreds of calls over the course of a week. The goal is to bring new ideas to our readers. Some analyst calls are far more bullish than others. Most calls may come with an implied upside of 10% or 25%. Then there are the far riskier calls in small cap stocks or low-priced stocks.
From this past week, there were three analyst calls that handily stood out over others for implied upside. These stocks were given upside of 50% and more!
ALSO READ: America's Worst Companies to Work For
Agile Therapeutics Inc. (AGRX) saw its quiet period come to an end, and the analyst upside targets are massive. The company came public at $6 back on May 23. Shares closed at $7.99 in Friday trading, and they have a post-IPO range of $5.05 to $8.20. Cantor Fitzgerald started it with a Buy and $17 price target. Janney started it with a Buy rating and $18 price target. William Blair and RBC also started it with Outperform ratings. Not many fresh IPOs are given price targets that could double.
Compugen Ltd. (CGEN) was started last Wednesday with an Outperform rating and a $14 price target at JMP Securities. The prior close was $9.06, but Compugen shares closed at $8.98 on Friday. Its 52-week range is $5.04 to $14.32. If the JMP analyst is accurate, this implies upside of more than 50%.
MeetMe Inc. (MEET) was started with a Buy rating and a serious upside target of $4.50 at Wunderlich Securities last Wednesday. The prior close was $1.93, but shares went above $2.25 by the time Friday rolled around, to close at $2.27. Even after the big move up last week, there is close to 100% upside if Wunderlich is correct.
Last week's coverage of the more aggressive calls with 50% to 100% implied upside (or more) included 3D Systems, Insmed and Orexigen. Monday's top analyst upgrades and downgrades included shares of AMD, BioCryst Pharmaceuticals, Burlington Stores, Dish Network, Express, Facebook, Nordstrom, SunPower, Teradata and many more.
ALSO READ: Ten Cars Americans Don't Want to Buy
As a reminder, low-priced and small-cap stocks are generally outside of the suitability requirements for most fiduciaries. These three companies would not be appropriate for any investors outside of the most speculative traders.